FACULTY
Mohit Khera, MD, MBA, MPH
Assistant Professor of Urology
Baylor College of Medicine
Houston, Texas

INTENDED AUDIENCE
Endocrinologists, urologists, primary care physicians, cardiologists, and specialists interested in the management and treatment of hypogonadism.

NEEDS ASSESSMENT
Despite evidence to the contrary, persistent concerns about the relationship between testosterone and the prostate continue to impede the treatment of hypogonadism. Mounting evidence demonstrates that there is a lack of association between testosterone therapy and prostate cancer progression, and preliminary studies have investigated the role of testosterone therapy in patient populations for whom it was once not considered. At present, there are strong indications that eugonadal testosterone levels play a protective role in the natural history of prostate cancer. Various studies support the proven benefits of testosterone therapy, which include increased lean body mass, decreased fat mass, and improved bone mineral density, sexual desire, and function. It is important to consider the effect of treatment with testosterone therapy, on the patient and his partner's sexual health as well as on their relationship. To overcome barriers to successful treatment of hypogonadism, physicians need targeted education focused on properly diagnosing hypogonadism, safely initiating testosterone therapy, and monitoring patients receiving testosterone therapy.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to...

  1. Evaluate new evidence related to the relationship between testosterone therapy, and prostate cancer risk
  2. Review the effect of treatment with testosterone therapy on the patient's sexual health and his partner
  3. Optimally manage hypogonadism to improve treatment outcomes for the patient and his partner

ACCREDITATION AND CERTIFICATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CogniMed Inc and Dannemiller. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the posttest and evaluation to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail cme@dannemiller.com.

CONTENT REVIEW STATEMENT
To resolve identified/potential conflicts of interest, the education content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

DISCLOSURE STATEMENT
It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA-approved indications.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff
Mark T. Nadeau, MD, MBA, FAAFP, Clinical Content Reviewer, has nothing to disclose.
Gordon Ringler, Project Manager, has nothing to disclose.

CogniMed Inc. Staff
Estelle Perera, Senior Director, Scientific Affairs and Program Design, and Medical Writer, has nothing to disclose.
Nancy Vogel, Production Editor, has nothing to disclose.

Faculty
Mohit Khera, MD, MBA, MPH, is a speaker for Auxillium Pharmaceuticals, Inc, and Lilly; is a consultant for Auxillium Pharmaceuticals, Inc, Coloplast, Endo Pharmaceuticals, and Lilly; and receives research support from Auxillium Pharmaceuticals.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by independent educational grants provided by Lilly USA, LLC.

This activity is an enduring material and consists of an audio recording. Successful completion is achieved by listening to the audio, reflecting on the content's implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 0.25 hour.

This activity was originally released September 16, 2014, and is eligible for credit through September 16, 2015.


© 2014 CogniMed Inc. All rights reserved.            TU16001             September 2014